Skip to main content

Corbus Pharmaceuticals Holdings, Inc 10-Q for FY2026 Q3

Corbus Pharmaceuticals Holdings, Inc. (CRBP)

10-Q 2026-11-10 For: 2026-09-30
View Original
Added on November 10, 2026

About this 10-Q

Corbus Pharmaceuticals Holdings, Inc filed this 10-Q on November 10, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

Corbus Pharmaceuticals Holdings reported that CRB-913’s 60 mg dose achieved mean 5% weight loss at 12 weeks. Nine-month 2026 net loss widened to $95.8 million from $58.0 million, with $115.3 million in cash at September 30, 2026. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Net loss
$37.75M
compared with a net loss of $23.34M a year earlier
Diluted EPS
-$1.81
compared with -$1.90 a year earlier